AN2 Therapeutics, Inc. (ANTX) Operating income 2021–2025
AN2 Therapeutics, Inc. (ANTX) annual operating income history from SEC filings — each fiscal year as reported.
-$38.1MFY2025 · since FY2021: -$21.6M → -$38.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$38.1M | +32.9% |
| FY2024 | -$56.8M | +18.4% |
| FY2023 | -$69.6M | -64.8% |
| FY2022 | -$42.3M | -95.9% |
| FY2021 | -$21.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ANTX financial trends
ANTX RevenueANTX Net incomeANTX Net marginANTX Gross profitANTX Gross marginANTX Operating marginANTX Operating cash flowANTX Free cash flowANTX Capital expendituresANTX Return on equityANTX Stock buybacksANTX Dividends paidANTX Total assetsANTX Total liabilitiesANTX Shareholders’ equityANTX overview →